SCHEMBL4312458

SCHEMBL4312458

Cc1cc(C(=O)C(=O)c2ccc(OCC(F)F)c(F)c2)ccc1OC(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ REN P00797 1/20 0.45
▸ CTSD P07339 1/20 0.45
▸ BACE1 P56817 1/20 0.45
▸ BACE2 Q9Y5Z0 1/20 0.45
▸ HTT P42858 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ TAS1R3 Q7RTX0 2/20 0.38
▸ TAS1R1 Q7RTX1 2/20 0.38
▸ CES2 O00748 1/20 0.37
▸ CES1 P23141 1/20 0.37
▸ PDE4B Q07343 7/20 0.37
▸ PDE4A P27815 6/20 0.37
▸ PDE4C Q08493 6/20 0.37
▸ PDE4D Q08499 6/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21387011 0.84 HDAC1 (0.46) BACE1HTTLMNAMAPK1RAB9A
SCHEMBL4309410 0.84 CES2 (0.44) HTTLMNARAB9ATAS1R3TAS1R1
SCHEMBL2797936 0.83 CES2 (0.44) RENCTSDBACE1BACE2HTT
SCHEMBL4315262 0.80 TAS1R3 (0.47) RENCTSDBACE1BACE2HTT
SCHEMBL8160796 0.80 CES2 (0.48) BACE1HTTLMNACES2CES1
SCHEMBL4308405 0.80 REN (0.41) RENCTSDBACE1BACE2PDE4B
SCHEMBL21387055 0.80 CES2 (0.53) HTTLMNATAS1R3TAS1R1CES2
SCHEMBL15956511 0.79 CES2 (0.47) BACE1HTTLMNACES2CES1
SCHEMBL2714544 0.78 HTT (0.49) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL4312454 0.78 REN (0.42) RENCTSDBACE1BACE2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 — — EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 — — US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP REN 2367/4885CTSD 88/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback